PremiumRatingsCelcuity’s Promising Clinical Trials and Strong Financial Position Justify Buy Rating Celcuity Approves Stock Plan Amendment at Annual Meeting Celcuity Inc. Earnings Call: Balancing Progress and Challenges PremiumRatingsCelcuity’s Strategic Advances and Clinical Trial Progress Bolster Buy Rating Celcuity Inc. Earnings Call Highlights Progress and Challenges Celcuity Stock (CELC) Dips Despite Promising Cancer Treatment in Pipeline PremiumPre-EarningsCelcuity Inc. (CELC) Q4 Earnings Cheat Sheet Oppenheimer biotech analyst holds an analyst/industry conference call Celcuity price target raised to $29 from $23 at Needham